Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
Background: The use of tyrosine kinase inhibitors has dramatically improved the prognosis of chronic myeloid leukemia (CML). Nilotinib has been reported to be associated with hypothyroidism and hyperthyroidism. Objectives: The current study aims to evaluate the prevalence of thyroid dysfunction in a...
Main Authors: | Khaleed J Khaleel, Ahmed H Matloob, Abdalsalam Hatim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Iraqi Journal of Hematology |
Subjects: | |
Online Access: | http://www.ijhonline.org/article.asp?issn=2072-8069;year=2018;volume=7;issue=1;spage=33;epage=38;aulast=Khaleel |
Similar Items
-
Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01) -
Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
by: Zaidi U, et al.
Published: (2019-02-01) -
The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021-11-01) -
Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review
by: Seyedeh Fatemeh Sadatmadani, et al.
Published: (2022-01-01) -
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
by: Emole J, et al.
Published: (2016-02-01)